Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
289 studies found for:    nf1
Show Display Options
Rank Status Study
1 Unknown  Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
Condition: Neurofibromatosis 1
Interventions: Drug: Lovastatin;   Drug: placebo pill
2 Recruiting Neurofibromatosis (NF) Registry Portal
Conditions: Neurofibromatosis 1;   Neurofibromatosis 2;   Schwannomatosis
Intervention:
3 Unknown  Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia
Conditions: Neurofibromatosis Type 1;   Tibial Dysplasia
Intervention:
4 Recruiting Effect of Lamotrigine on Cognition in NF1
Condition: Neurofibromatosis Type 1
Interventions: Drug: Lamotrigine;   Drug: Placebo
5 Recruiting Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1
Condition: Neurofibromatosis Type 1
Intervention: Other: Neuropsychological examination and quality of life measures
6 Recruiting Genetic Evaluation of NF1 and Scoliosis Patients
Conditions: Neurofibromatosis 1;   Scoliosis
Intervention: Other: Cheek swab
7 Recruiting Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
Conditions: NF1;   Neurofibromatosis;   Plexiform Neurofibromas
Intervention: Drug: Cabozantinib
8 Active, not recruiting Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
Conditions: Neurofibromatosis Type I;   Legius Syndrome
Intervention:
9 Completed Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
Conditions: Tuberous Sclerosis;   Neurofibromatoses;   Angiofibroma;   Neurofibroma
Interventions: Drug: Skincerity;   Drug: Skincerity plus sirolimus/rapamycin;   Drug: Skinercity plus sirolimus/rapamycin
10 Active, not recruiting Modifying Genes in Neurofibromatosis 1
Condition: Neurofibromatosis 1
Intervention: Other: No intervention
11 Recruiting Neurofibromatosis Type 1 Patient Registry
Condition: Neurofibromatosis Type 1
Intervention:
12 Unknown  Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
Condition: Neurofibromatosis Type 1
Intervention:
13 Active, not recruiting Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Neurofibromas
Intervention: Drug: Tasigna
14 Active, not recruiting Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   Neurofibromas
Intervention: Drug: Gleevec
15 Suspended Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Plexiform Neurofibromas
Intervention: Drug: Sutent®/Sunitinib
16 Completed A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers
Condition: Healthy
Interventions: Drug: Pregabalin 150mg;   Drug: Pregabalin 300mg
17 Completed Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I
Conditions: Neurofibromatosis Type 1;   Von Recklinghausen Disease;   NF1
Intervention:
18 Active, not recruiting Neurobiology and Treatment of Reading Disability in NF-1
Conditions: Neurofibromatosis Type 1;   Reading Disabilities
Interventions: Behavioral: Tutoring Program I;   Behavioral: Tutoring Program II
19 Recruiting Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Intervention: Drug: Everolimus
20 Recruiting MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
Condition: Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Intervention: Drug: PD-0325901

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years